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AIM: To compare the dimensions of quality of life in the stages of chronic kidney disease and the influence of
sociodemographic, clinical and laboratory data.
INTRODUCTION: The information available on the quality of life of patients on conservative treatment and the
relationship between the quality of life and glomerular filtration rate is limited.
METHODS: 155 patients in stages 1–5 of chronic kidney disease and 36 in hemodialysis were studied. Quality of life
was rated by the Medical Outcomes Study Short Form 36-Item (SF-36) and functional status by the Karnofsky
Performance Scale. Clinical, laboratory and sociodemographic variables were investigated.
RESULTS: Quality of life decreased in all stages of kidney disease. A reduction in physical functioning, physical role
functioning and in the physical component summary was observed progressively in the different stages of kidney
disease. Individuals with higher educational level who were professionally active displayed higher physical
component summary values, whereas men and those with a higher income presented better mental component
summary values. Older patients performed worse on the physical component summary and better on the mental
component summary. Hemoglobin levels correlated with higher physical component summary values and the
Karnofsky scale. Three or more comorbidities had an impact on the physical dimension.
CONCLUSION: Quality of life is decreased in renal patients in the early stages of disease. No association was detected
between the stages of the disease and the quality of life. It was possible to establish sociodemographic, clinical and
laboratory risk factors for a worse quality of life in this population.
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INTRODUCTION
The incidence and prevalence of patients with chronic
kidney disease (CKD) is increasing worldwide. In Brazil, the
Brazilian Society of Nephrology has collected information
annually on patients with end-stage renal disease (ESRD)
since 1999 and made it available on the Society’s website.
1 In
2008, the estimated number of patients in dialysis amounted
to 87,044, of whom 90% were on hemodialysis and 10% on
peritoneal dialysis.
Some studies have evaluated the quality of life (QOL) of
patients undergoing dialysis, but there is limited informa-
tion available on the QOL of patients on conservative
treatment of CKD and the relationship between QOL and
the early stages of the disease. The QOL of these patients
seems to be poorer than that of the general population, but
better than for patients on dialysis.
2,3 Certain factors such as
anemia, associated diseases and early treatment by a
nephrologist appear to have an impact on the QOL of these
patients.
3–5
The objectives of this cross-sectional study were to assess
the QOL of patients with stages 1–5 CKD on conservative
treatment in order to identify a possible association between
QOL and progression of kidney insufficiency. The results
were compared with those obtained for patients on
hemodialysis. Sociodemographics, clinical and laboratory
data were also evaluated.
METHODS AND MATERIALS
A total of 202 patients were randomly selected, including
165 with non-dialytic CKD followed up at the CKD
outpatient clinic of the Division of Nephrology, Federal
University of Sa ˜o Paulo, Sa ˜o Paulo, Brazil, and 37 patients
undergoing hemodialysis at the institution. A sample of
30% of all patients under follow-up was selected using a
systematic random sampling method. Initially, a list of all
patients with CKD (and another for those on hemodialysis)
was made, and a consecutive number was given to each one.
Then, a starting point was chosen at random and every fifth
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991record (this interval was prespecified) on the list was
selected. The procedure was repeated until the estimated
number of participants was reached. Among the patients
initially contacted, 11 refused to participate in the study.
The subjects were interviewed prior to the medical visits
or after the hemodialysis session in a separate room by two
trained interviewers. Included patients should be on
hemodialysis treatment for .6 months and ,6 years and
were submitted to a conventional in-center hemodialysis
regimen consisting of three weekly hemodialysis sessions
lasting 4 hours each. Patients were excluded if they did not
consent to participate, were younger than 18 years or had
hearing, speech or cognitive deficits that would impair
understanding of the questions.
The protocol was approved by the ethics committee of the
institution, and all subjects gave written informed consent to
participate in the study.
To assess the QOL, we used the Medical Outcomes Study
Short Form 36-Item Health Survey (SF-36), a generic
instrument translated and validated in Brazilian patients
with ESRD.
6,7 This instrument is divided into 8 dimensions:
physical functioning, physical role functioning, pain, gen-
eral health, vitality, social role functioning, emotional role
functioning, mental health. The results of each scale vary
from 0 to 100 (worse to best possible status). The physical
and mental components of the 8 scales were combined into a
physical component summary (PCS) and a mental compo-
nent summary (MCS). The 2 summary measures were
Table 1 - Stages of chronic kidney disease.
11
Stage of CKD Glomerular filtration rate (ml/min) Description
1 $90 Kidney damage with normal renal function
Presence of proteinuria
2 60–89 Kidney damage with small decrease in GFR
3 30–59 Kidney damage with moderate decrease in GFR
4 15–29 Kidney damage with large decrease in GFR
5 ,15 Kidney failure, end-stage renal disease
CKD=chronic kidney disease, GFR=glomerular filtration rate.
Table 2 - Sociodemographic characteristics, according to the stage of chronic kidney disease (CKD).
Stage of CKD
1 and 2 (n=18) 3 (n=52) 4 and 5 (n=85) Hemodialysis (n=36)
Gender
Male 9 (50) 30 (57.7) 49 (57.6) 20 (55.6)
Female 9 (50) 22 (42.3) 36 (42.4) 16 (44.4)
Age (years) 51.8¡10.6 58.3¡16.9 58.1¡16.5 52.5¡15.9
Race
Caucasian 13 (72.2) 44 (84.6) 66 (77.6) 23 (63.9)
Black/mulatto 5 (27.8) 7 (13.5) 16 (18.8) 13 (36.1)
Asian 0 1 (1.9) 3 (3.5) 0
Marital status
Unmarried/separated 5 (27.8) 10 (20.0) 27 (33.3) 15 (41.7)
Married 10 (55.6) 34 (68.0) 46 (56.8) 18 (50.0)
Widowed 3 (16.7) 6 (12.0) 8 (9.9) 3 (8.3)
Education level
Illiterate 2 (11.1) 5 (9.6) 7 (8.2) 4 (11.1)
Elementary/middle school 8 (44.4) 34 (65.4) 46 (54.1) 22 (61.1)
High-school/college 8 (44.4) 13 (25.0) 32 (36.7) 10 (27.8)
Occupation
Employed 5 (50.0) 8 (33.3) 23 (46.0) 3 (15.8)
Retired/sick leave 5 (50.0) 12 (50.0) 23 (46.0) 14 (73.7)
Unemployed 0 4 (16.7) 4 (8.0) 2 (10.5)
Housing
Alone 3 (16.7) 5 (9.6) 10 (11.8) 3 (8.6)
With friends and/or relatives 15 (83.3) 47 (90.4) 75 (88.2) 32 (91.4)
Individual income
Zero 4 (22.2) 7 (14.0) 13 (15.7) 3 (9.1)
1–2 minimum wages 5 (27.8) 23 (46.0) 36 (43.4) 12 (36.4)
3–5 minimum wages 7 (38.9) 15 (30.0) 20 (24.1) 11 (33.3)
.5 minimum wages 2 (11.1) 5 (10.0) 14 (16.9) 7 (21.2)
Socioeconomic status
A/B 4 (40.0) 7 (31.8) 14 (29.8) 7 (31.8)
C 4 (40.0) 9 (40.9) 22 (46.8) 10 (45.5)
D/E 2 (20.0) 6 (27.3) 11 (23.4) 5 (22.7)
Data are reported as number (%) or mean¡SD.
Monthly minimum wage: US$210.00.
No statistically significant differences were observed among CKD groups for these variables.
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992standardized so as to have a mean value of 50 and a
standard deviation (SD) of 10 in the general population.
7
The Karnofsky Performance Status (KPS)
8 was used to
assess self-sufficiency and functional capacity, which deter-
mines functional impairment in the performance of activities
of daily living, using a score ranging from 100 (indicating no
evident disease) to 0 (indicating death). This instrument has
been widely used in studies on patients with CKD.
The socioeconomic level of the patients was evaluated
according tothecriteria of theBrazilian Association of Research
Companies, which are recognized in Brazil and divide the
population into social classes A, B, C, D and E, with class A
corresponding to the highest socioeconomic level.
9 Other
sociodemographic and clinical variables were also analyzed
in an attempt to identify a possible association with QOL.
Glomerular filtration rate (GFR) was estimated by the
creatinine clearance according to the formula of Cockcroft
and Gault
10 adjusted to 1.73 m
2 of body surface area, using
the latest serum creatinine measurement available for each
patient. The stages of CKD were classified as suggested by
the Kidney Disease Outcomes Quality Initiative
11 and are
presented in Table 1.
For the purpose of analysis, CKD stages 1 and 2 and
stages 4 and 5 were combined, because of the small number
of patients in each group, to increase the power of statistical
comparisons between groups.
Statistical analysis
The results are presented as percentage or mean¡SD.
Chi-square tests were performed to compare categorical
variables. For the continuous variables, we used Student’s
unpaired t-test to compare two groups, and ANOVA to
compare more than two groups. Whenever the ANOVA test
result was significant, we then compared the groups two by
two. Pearson’s correlation test was employed to correlate
the PCS and the MCS and KPS results with the other
continuous variables. Statistical significance was set at
p,0.05, and all tests performed were two-tailed.
RESULTS
Of the 191 patients who participated in the study, 155
were predialysis CKD patients and 36 were on HD. The total
sample of predialysis CKD patients was divided into five
Table 3 - Clinical and laboratory parameters according to the stage of CKD.
Stage of CKD
1 and 2 (n=18) 3 (n=52) 4 and 5 (n=85) Hemodialysis (n=36)
Etiology of CKD
Hypertension 3 (16.7) 9 (17.3) 22 (25.9) 8 (22.2)
Diabetes mellitus 4 (22.2) 10 (19.2) 21 (24.7) 12 (33.3)
Glomerulonephritis 2 (11.1) 2 (3.8) 7 (8.2) 1 (2.8)
Other/unknown 9 (50.0) 31 (59.6) 35 (41.2) 12 (41.7)
Ambulatory follow-up (months) 30.8¡22.9 26.6¡28.2 33.0¡41.9 –
Time on HD (months) – – – 63.8¡22.2
No. of comorbidities
0–2 18 (100.0) 43 (82.7) 73 (85.9) 17 (47.2)*
3 or more 0 9 (17.3) 12 (14.1) 19 (52.8)
Hemoglobin (g/dl) 14.6¡1.9{ 13.0¡1.6{ 11.8¡1.7 11.2¡1.8
Serum urea (mg/dl) 39.7¡19.6{ 62.0¡32.9{ 95.4¡41.21 137.6¡30.6
Serum ionized calcium (mg/dl) 1.33¡0.07 1.33¡0.18 1.29¡0.11 1.19¡0.12*
Serum phosphorus (mg/dl) 3.3¡0.9" 3.7¡0.7 4.3¡1.0 4.3¡1.6
Data are reported as number (%) or mean¡SD.
*p,0.001 compared with stages 1–2, 3 and 4–5.
{p,0.001 compared with stages 3, 4–5 and hemodialysis.
{p,0.001 compared with stages 4–5 and hemodialysis.
1p,0.001 compared with hemodialysis.
"p,0.001 compared with stages 4–5; p,0.05 compared with stage 3 and hemodialysis.
Table 4 - Quality of life according to stage of chronic kidney disease (CKD).
Stages 1 and 2 (N=18) Stage 3 (N=52) Stages 4 and 5 (N=85) Hemodialysis (N=36)
Physical functioning 73.9¡30.9 69.0¡24.6 67.1¡27.9 61.5¡ 29.3
Physical role functioning 61.1¡47.9 55.8¡39.8 52.3¡40.8 48.6¡40.1
Pain 66.5¡27.4 57.2¡23.0 61.4¡26.0 59.8¡25.1
General health 54.3¡16.0 58.2¡19.9 51.2¡20.6 51.7¡21.2
Vitality 61.9¡24.6 56.7¡25.1 58.2¡25.5 54.3¡22.2
Social role functioning 75.0¡30.6 70.2¡30.5 72.4¡27.7 63.7¡33.7
Emotional role functioning 46.3¡45.9 68.6¡41.4 72.9¡40.0 65.7¡44.0
Mental health 65.3¡29.8 64.4¡24.2 65.7¡21.4 64.0¡24.5
PCS 47.9¡11.8 44.4¡8.8 43.1¡10.4 42.2¡9.9
MCS 43.5¡14.7 46.0¡13.7 47.7¡10.9 45.6¡14.6
Karnofsky score 88.0¡12.3 90.8¡11.0 87.8¡14.7 85.2¡11.2
PCS=physical component summary; MCS=mental component summary.
Data are reported as mean¡SD.
No statistically significant differences were observed among CKD and HD groups for these variables.
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993stages according to GFR and subsequently grouped into
three groups (stages 1+2, 3 and 4+5).
The patients in the three groups of CKD stage and those
on hemodialysis were similar with regard to their socio-
demographic characteristics (Table 2).
With respect to laboratory variables, the groups differed
in some characteristics, as shown in Table 3.
QOL, as evaluated by the means of SF-36 domains, was
low for most dimensions in all stages and was not
statistically significant different among the patients in the
three groups of CKD stage or on hemodialysis. The
dimensions showing lower values in stages 1 and 2 were
emotional role functioning and general health; in stage 3,
physical role functioning and vitality; and in stages 4 and 5
and hemodialysis, physical role functioning and general
health. No difference was observed among the groups
regarding the PCS, the MCS or on the KPS (Table 4).
Evaluating sociodemographic data, patients who had a
higher educational level performed better than the others in
mean PCS. As for the patients’ mean MCS scores, males and
Asians showed better results and those with no individual
monthly income had lower values than those with some
income. The KPS scores showed no statistically significant
differences related to demographic data, except for occupa-
tion: those who were professionally active performed better
(Table 5). No significantly difference was found between the
mean PCS and MCS and the KPS scores when the patients
were divided by the etiology of CKD and the occurrence of
hospitalization.
With regard to age, there was a negative correlation with
the mean PCS and a positive correlation with the mean MCS
scores. Hemoglobin level was positively correlated with
PCS and KPS, whereas the serum phosphorus levels
showed a negative correlation with MCS (Table 6).
Evaluating patients for the number of comorbidities, we
found that those with three or more were older, retired and
diabetic. Low levels of calcium and high levels of urea were
also found in patients with more comorbidities. With respect
to the QOL, patients with more comorbidities had worse
rates in the assessment of functional capacity (assessed by
both SF-36 and the KPS), physical role functioning and PCS.
DISCUSSION
Our results indicate low QOL scores in the early stages of
CKD, although we have not demonstrated a significant
decrease in QOL progressively in the different stages of
renal disease. Not only were mean values of the physical
components reduced as early as stages 1–3 of CKD but
mental health also seemed to be compromised, based on the
mean values of the SF-36 scores, which were below 70 in
most dimensions. Normal healthy populations usually have
scores above this level in most studies
7.
Few studies have evaluated the QOL of patients in the
early stages of CKD, especially in the first two stages, or
sought to relate QOL and GFR.
3,12 In these studies, a
significant reduction in QOL was also not identified
according to the progression of renal dysfunction. What is
Table 5 - Relation between sociodemographic data,
clinical and laboratory parameters and quality of life
(QOL).
PCS (n= 191) MCS (n=191) KPS (n=171)
Gender
Male 44.3¡10.2 48.1¡12.4* 86.6¡14.5
Female 43.0¡9.9 44.3¡13.0 89.2¡10.4
Ethnicity
Caucasian 43.2¡10.4 46.9¡12.3 88.4¡13.2
Black/mulatto 45.9¡8.8 43.6¡13.9 86.3¡11.8
Asian 43.7¡11.2 60.2¡4.2{ 80.0¡14.1
Education level
Illiterate 39.6¡9.3 42.7¡14.0 81.7¡10.3
Elementary/middle
school
42.1¡9.7 46.9¡12.4 88.1¡13.7
High school/
college
47.7¡9.7{ 46.6¡13.1 89.2¡11.7
Occupation
Employed 46.1¡9.4 47.2¡10.6 92.7¡9.9
Retired/sick leave 40.9¡10.91 48.8¡12.8 85.1¡14.61
Unemployed 44.8¡8.3 40.1¡12.9 90.0¡10.5
Individual income
Zero 44.0¡10.3 40.3¡12.7" 89.4¡11.6
1–2 minimum
wages
42.4¡10.6 47.8¡13.2 85.3¡14.5
3–5 minimum
wages
43.5¡8.9 45.7¡12.5 89.1¡11.8
.5 minimum
wages
46.5¡10.3 50.4¡11.1 89.0¡12.2
PCS=physical component summary; MCS=mental component summary.
*p,0.05 compared with females.
{p,0.05 compared with Caucasian and p,0.001 compared with black/
mulatto.
{p,0.05 compared with illiterate and p,0.001 compared with
elementary/middle school.
1p,0.05 compared with employed.
"p,0.05 compared with 1–2 minimum wages and .5 minimum wages.
Data are reported as mean¡SD. Monthly minimum wage=US$210.00.
No statistically significant differences were observed for the other
variables.
Table 6 - Pearson correlation coefficients among demographic data, clinical and laboratory parameters and quality of
life (QOL).
PCS (N=191) MCS (N=191)
Karnofsky score
(N=117)
Age (years) –0.196{ 0.229{ –0.060
Time of outpatient follow-up (months) 0.077 –0.009 0.103
Time on HD (months) –0.225 0.152 –0.084
Hemoglobin (g/dl) 0.173* 0.000 0.258{
Serum ionized calcium (mg/dl) 0.068 –0.036 0.183
Serum phosphorus (mg/dl) –0.089 –0.160* 0.026
Serum urea (mg/dl) –0.124 –0.007 –0.131
PCS=physical component summary; MCS=mental component summary.
*p,0.05.
{p,0.01.
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994reported more frequently in the literature is a decrease in
the physical domains of QOL in the advanced stages of
CKD, which was also identified in our study.
13–16
In our study, the hemoglobin levels showed a correlation
with better PCS and KPS scores. In the literature, the impact
of anemia on QOL in CKD is well described from the
predialysis CKD phases through ESRD.
17,18 We observed
that a greater number of comorbidities were associated with
older age, diabetes and unemployment or retired status. The
presence of three or more comorbidities had a negative
impact on the domains physical functioning, physical role
functioning and PCS, and on KPS. Some reports have
suggested that the presence of comorbidities is a major
determinant of a decline in QOL.
19,20 Diabetes mellitus has
also been associated with low QOL.
21
It is known, however, that the subjective assessment of
QOL is multifactorial, and therefore the progression of renal
dysfunction may not be the only determinant in its
deterioration. In our study, more sociodemographic factors
(age, ethnicity, gender, professional activity, education,
income) were associated with decreased QOL than physical
factors. Added to this, it is possible that subjective factors
such as adaptation to disease and treatment, satisfaction
with the medical staff and social support, among others,
may interfere directly in the assessment of QOL, but were
not evaluated in this study. The influence of these different
factors on the assessment of QOL may explain the difficulty
in establishing a linear relation with the GFR.
Some limitations of the present study are the relatively
small sample size to detect significant differences between
the stages of CKD and the difficulties we encountered in
recruiting subjects in the initial stages of the disease. The
cross-sectional design of the study only permitted us to
determine associations between variables and not causal
relationships. Thus, longitudinal studies that take into
account qualitative assessments should be conducted to
seek a better understanding of the influence of the
progression of CKD on QOL.
In conclusion, in this study, we observed a negative
impact on the QOL of patients in the early stages of CKD,
although we were not able to detect a significant association
between the stages of the disease and the SF-36 domains.
However, it was possible to establish sociodemographic,
clinical and laboratory risk factors for a worse QOL in this
population (educational level, gender, individual income,
professional activity, age, hemoglobin levels, serum phos-
phorus levels, diabetes and comorbidities). Although
several of the variables that were associated with alterations
in the QOL cannot be changed (e.g., age, gender, ethnicity),
efforts should be made to decrease the effects of those
factors that can be changed, such as improving the
hemoglobin levels and adequately managing the comorbid-
ities. The health professionals responsible for the care
provided to this population should ideally be familiar with
and trained in the application of the QOL assessment tools,
which may be valuable in the global assistance of these
patients, even in the earlier stages of disease, and allow
timely health care interventions in the course of the disease.
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